Vorapaxar (MK-5348) - 99%, high purity , CAS No.618385-01-6, Antagonist of PAR1

Item Number

V413905

• Synonyms: Vorapaxar | 618385-01-6 | Sch 530348 | SCH-530348 | SCH530348 | Vorapaxar free base | UNII-ZCE93644N2 | CHEBI:82702 | ZCE93644N2 | MK-5348 | CHEMBL493982 | DTXSID201009336 | 618385-01-6 (free base) | [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dod
• Specifications & Purity: Moligand™, ≥99%
• Biochemical and Physiological Mechanisms: Vorapaxar (SCH 530348, MK-5348) is a potent and orally active thrombin receptor (PAR-1) antagonist with K_i of 8.1 nM.
• Storage Temp: Store at -20°C
• Shipped In: Ice chest + Ice pads
• Grade: Moligand™
• Action Type: ANTAGONIST
• Mechanism of action: Antagonist of PAR1

Product Description

Information

Vorapaxar (MK-5348) Vorapaxar (SCH 530348, MK-5348) is a potent and orally active thrombin receptor (PAR-1) antagonist with K i of 8.1 nM.

Targets

PAR-1 (Cell-free assay) 8.1 nM(Ki)

In vitro

SCH 530348 is a synthetic tricyclic 3-phenylpyridine and an orally active himbacine-based thrombin-receptor antagonist. SCH 530348 shows potent inhibition of thrombin-induced platelet aggregation with an IC50 of 47 nM and haTRAP-induced platelet aggregation with an IC50 of 25 nM, whereas it shows no inhibition of platelet aggregation induced by other agonists such as ADP, collagen and a PAR-4 agonist peptide. SCH 530348 also has no affect on the prothrombin time (PT), partial thromboplastin time (PTT), or activated partial thromboplastin time (aPTT). Moreover, SCH 530348 causes no increase in the bleeding time or in surgical bleeding compared with inactive control. SCH530348 is found to be selective for PAR-1 when tested over a number of ion channels and receptors, including PAR-4 receptor.

In vivo

SCH 530348 is well absorbed in rat (68%; 10 mg/kg) and in monkey (82%; 1 mg/kg) models. T_max is observed at about 3 h in rats and 1 h in monkeys. The elimination half-life is 5.1 h in rats and 13 h in monkeys. The oral bioavailability is 33% in rats and 86% in monkeys. In preclinical studies in cynomolgus monkey platelets, oral administration of SCH 530348 at a dose greater than 0.1 mg/kg resulted in 100% inhibition of thrombin-receptor agonist peptide (TRAP)-induced platelet aggregation for 24 h with partial recovery occurring at 48 h.